MINERVA IMAGING ApS - CVR: 34077746

2022, DKK

30.06.2023

Bruttoresultat

72.802'

Primær drift

22.677'

Årets resultat

16.212'

Aktiver

171''

Kortfristede aktiver

97.481'

Egenkapital

53.919'

Afkastningsgrad

13 %

Soliditetsgrad

32 %

Likviditetsgrad

126 %

Resultat

30.06.2023

Årsrapport	2022 30.06.2023	2021 30.05.2022	2020 30.06.2021	2019 02.09.2020	2018 22.06.2019	2017 25.06.2018	2016 20.06.2017	2015 16.06.2016
Nettoomsætning
Bruttoresultat	72.802.069	50.461.697	28.061.085	12.326.683	9.242.892	7.913.087	3.498.275	0
Resultat af primær drift	22.677.090	20.742.452	12.984.545	5.622.343	5.303.937	5.787.131	2.530.734	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	8.620	86.209	63.250	18.596	84.685	0	0	0
Finansieringsomkostninger	-1.736.186	-470.102	-289.521	-78.301	-26.478	-179.264	-31.714	-20.580
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	20.949.524	20.351.079	12.757.182	5.560.893	5.360.896	5.607.165	2.498.562	342.153
Resultat	16.212.180	15.721.167	10.262.982	4.330.828	4.179.367	4.369.572	1.947.828	257.406
Forslag til udbytte	0	-1.000.000	0	0	-600.000	-1.500.000	0	-1.400.000

Aktiver

30.06.2023

Årsrapport	2022 30.06.2023	2021 30.05.2022	2020 30.06.2021	2019 02.09.2020	2018 22.06.2019	2017 25.06.2018	2016 20.06.2017	2015 16.06.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	94.538.027	38.591.978	15.661.363	12.684.095	6.132.313	7.246.264	3.627.451	906.366
Likvider	2.942.999	1.896.177	19.644.229	5.230.705	7.490.762	5.399.385	938.479	1.377.178
Kortfristede aktiver	97.481.026	40.488.155	35.305.592	17.914.800	13.623.075	12.645.649	4.565.930	2.283.544
Immaterielle aktiver og goodwill	0	0	0	0	0	72.096	72.798	73.256
Finansielle anlægsaktiver	19.598.993	18.606.007	8.124.611	8.125.379	70.848	72.096	72.798	73.256
Materielle aktiver	53.887.903	21.623.497	6.551.112	2.305.622	1.854.399	200.079	28.201	0
Langfristede aktiver	73.486.896	40.229.504	14.675.723	10.431.001	1.925.247	272.175	100.999	73.256
Aktiver	170.967.922	80.717.659	49.981.315	28.345.801	15.548.322	12.917.824	4.666.929	2.356.800

Aktiver

30.06.2023

Passiver

30.06.2023

Årsrapport	2022 30.06.2023	2021 30.05.2022	2020 30.06.2021	2019 02.09.2020	2018 22.06.2019	2017 25.06.2018	2016 20.06.2017	2015 16.06.2016
Forslag til udbytte	0	1.000.000	0	0	600.000	1.500.000	0	1.400.000
Egenkapital	53.918.666	38.989.771	23.268.604	13.005.622	9.274.794	6.595.427	2.225.856	1.678.027
Hensatte forpligtelser	440.000	992.674	78.810	110.211	87.958	4.148	816	0
Langfristet gæld til banker	1.113.071	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	13.371.373	10.204.844	5.745.912	3.317.439	0	2.886.655	768.508	323.054
Kortfristede forpligtelser	77.394.866	40.735.214	26.633.901	15.229.968	6.185.570	6.318.249	2.440.257	678.773
Gældsforpligtelser	116.609.256	40.735.214	26.633.901	15.229.968	6.185.570	6.318.249	2.440.257	678.773
Forpligtelser	116.609.256	40.735.214	26.633.901	15.229.968	6.185.570	6.318.249	2.440.257	678.773
Passiver	170.967.922	80.717.659	49.981.315	28.345.801	15.548.322	12.917.824	4.666.929	2.356.800

Passiver

30.06.2023

Nøgletal

30.06.2023

Årsrapport	2022 30.06.2023	2021 30.05.2022	2020 30.06.2021	2019 02.09.2020	2018 22.06.2019	2017 25.06.2018	2016 20.06.2017	2015 16.06.2016
Afkastningsgrad	13,3 %	25,7 %	26,0 %	19,8 %	34,1 %	44,8 %	54,2 %	Na.
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	30,1 %	40,3 %	44,1 %	33,3 %	45,1 %	66,3 %	87,5 %	15,3 %
Payout-ratio	Na.	6,4 %	Na.	Na.	14,4 %	34,3 %	Na.	543,9 %
Gældsdæknings-nøgletal	1.306,1 %	4.412,3 %	4.484,8 %	7.180,4 %	20.031,5 %	3.228,3 %	7.979,9 %	Na.
Soliditestgrad	31,5 %	48,3 %	46,6 %	45,9 %	59,7 %	51,1 %	47,7 %	71,2 %
Likviditetsgrad	126,0 %	99,4 %	132,6 %	117,6 %	220,2 %	200,1 %	187,1 %	336,4 %

Resultat

30.06.2023

Gæld

30.06.2023

Årsrapport

30.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 30.06.2023)

Information om virksomhedens regnskabsklasse:The annual report for Minerva Imaging ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises. The annual report is presented in DKK.

Oplysning om pantsætninger og sikkerhedsstillelser:8. Charges and security For security for the company's and the group's bank commitments, the company has provided security in company assets representing a nominal value of 20.000 t.kr. This security comprises the assets below, stating the carrying amounts: DKK in thousands Other fixtures, fittings, tools and equipment 11.686 Trade receivables 19.057 Furthermore, the company has provided security in investments in group enterprises with a carrying amount of 18.545 t.kr., cf. note 5, for security for the group's bank commitment. The company has guaranteed the subsidiary, Bioadvice A/S, bank commitment. Fixtures, fittings, tools, and equipment representing a carrying amount of 42.202 t.kr.at 31 December 2022, cf. note 4, have been financed by means of finance leases. At 31 December 2022, this lease liability totals 42.828 t.kr.

Beretning

30.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-06-28

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Managing Director have approved the annual report of Minerva Imaging ApS for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Description of key activities of the company Minerva Imaging’s vision is to become the preferred partner for global biotech and pharma companies for development of radiopharmaceuticals covering all steps from lead optimization to first-in-human studies. We aim to excel in delivering customized radiopharmaceutical research and serve as an extended research team to our collaborators. We have built a global leading R&D platform for targeted radionuclide therapy and Contract Development and Manufacturing (CDMO) to enable integrated planning and faster execution of promising new radionuclide theragnostic projects. We are in a fast-paced environment, where our researchers directly impact the advancement of new, and lifesaving drugs for cancer patients. We have the ambition to make a difference for our clients, collaborating on advancing new treatment modalities for seriously ill patients.